Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices.
Bruch’s membrane
VEGF
biomaterials
nanocarriers
neuroprotection
ocular drug delivery
retina
retinal pigment epithelium
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
04
2020
accepted:
06
10
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 years old people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting of intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, the development of biomaterials-based approaches for a personalized and controlled delivery of therapeutic drugs and biomolecules represents the main challenge for the defeat of this neurodegenerative disease. Here we present a critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In the first part we expose the physiological and clinical aspects of the disease, focusing on the multiple factors that give origin to the disorder and highlighting the contribution of these factors to the triggering of each step of the disease. Then we analyze available and under development biomaterials-based drug-delivery devices (DDD), taking into account the anatomical and functional characteristics of the healthy and ill retinal tissue.
Identifiants
pubmed: 33224926
doi: 10.3389/fbioe.2020.549089
pmc: PMC7670958
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
549089Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB002520
Pays : United States
Informations de copyright
Copyright © 2020 Jemni-Damer, Guedan-Duran, Fuentes-Andion, Serrano-Bengoechea, Alfageme-Lopez, Armada-Maresca, Guinea, Pérez-Rigueiro, Rojo, Gonzalez-Nieto, Kaplan and Panetsos.
Références
Int J Nanomedicine. 2013;8:495-503
pubmed: 23439842
Artif Cells Nanomed Biotechnol. 2018;46(sup2):1074-1081
pubmed: 29916734
Drug Discov Today. 2008 Feb;13(3-4):135-43
pubmed: 18275911
Acta Biomater. 2016 Oct 1;43:327-337
pubmed: 27481290
Ann Biomed Eng. 2015 Nov;43(11):2609-17
pubmed: 25835212
Arch Ophthalmol. 2007 Mar;125(3):309-17
pubmed: 17353400
Pharm Res. 2014 Mar;31(3):742-53
pubmed: 24022682
Curr Drug Targets. 2005 May;6(3):363-71
pubmed: 15857294
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):493-497
pubmed: 28906084
Eur J Pharm Sci. 2019 Sep 1;137:104993
pubmed: 31302214
Lab Chip. 2011 Aug 21;11(16):2744-52
pubmed: 21698338
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
Drug Discov Today. 2019 Aug;24(8):1470-1482
pubmed: 31202673
Prog Retin Eye Res. 2014 Sep;42:27-43
pubmed: 24819336
Int J Pharm. 2014 Sep 10;472(1-2):262-75
pubmed: 24950367
J Biomed Mater Res A. 2015 Oct;103(10):3148-56
pubmed: 25773970
Drug Discov Today. 2017 Feb;22(2):416-423
pubmed: 27818255
Science. 2005 Apr 15;308(5720):385-9
pubmed: 15761122
Br J Pharmacol. 2007 Mar;150(5):552-8
pubmed: 17245366
World J Pharmacol. 2013;2(2):47-64
pubmed: 25590022
Transl Vis Sci Technol. 2019 Jan 22;8(1):12
pubmed: 30701127
J Physiol Anthropol. 2016 Mar 15;35:9
pubmed: 26980095
J Med Chem. 2018 Feb 22;61(4):1622-1635
pubmed: 29400470
Am J Hum Genet. 2005 Jul;77(1):149-53
pubmed: 15895326
Pharm Res. 2009 May;26(5):1197-216
pubmed: 18758924
J Am Chem Soc. 2010 Jul 21;132(28):9540-2
pubmed: 20568765
Biol Pharm Bull. 2017;40(2):145-150
pubmed: 28154252
Clin Genet. 2013 Aug;84(2):160-6
pubmed: 23713713
Curr Eye Res. 2016 Sep;41(9):1216-22
pubmed: 26764892
Ophthalmology. 2012 Jul;119(7):1388-98
pubmed: 22555112
Invest Ophthalmol Vis Sci. 1991 May;32(6):1785-90
pubmed: 2032801
Surv Ophthalmol. 1996 Nov;41 Suppl 1:S9-18
pubmed: 8970245
Biomed Microdevices. 2009 Oct;11(5):959-70
pubmed: 19396548
Nano Lett. 2012 Oct 10;12(10):5355-61
pubmed: 22985294
Curr Opin Pharmacol. 2017 Oct;36:44-51
pubmed: 28843865
J Ocul Pharmacol Ther. 2016 Apr;32(3):135-44
pubmed: 26811883
Retina. 2017 Apr;37(4):609-610
pubmed: 28207610
Nat Commun. 2019 Feb 18;10(1):804
pubmed: 30778060
Pharmacol Rep. 2006 May-Jun;58(3):353-63
pubmed: 16845209
Arch Ophthalmol. 2011 Jan;129(1):75-80
pubmed: 21220632
Retina. 2004 Oct;24(5):676-98
pubmed: 15492621
J Biomed Mater Res A. 2018 Nov;106(11):2795-2804
pubmed: 29752862
Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1397-1407
pubmed: 27855494
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):227-38
pubmed: 26032290
Adv Drug Deliv Rev. 2018 Feb 15;126:67-95
pubmed: 29339145
Surv Ophthalmol. 2005 Mar-Apr;50(2):167-82
pubmed: 15749307
Anesthesiology. 2005 Jun;102(6):1182-9
pubmed: 15915031
Clin Ophthalmol. 2011;5:1043-9
pubmed: 21845032
J Control Release. 2017 Feb 28;248:96-116
pubmed: 28087407
Tissue Eng Part C Methods. 2009 Sep;15(3):333-344
pubmed: 19196125
Prog Retin Eye Res. 2004 May;23(3):253-81
pubmed: 15177203
Drugs Aging. 2006;23(5):421-45
pubmed: 16823995
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
Biomaterials. 2002 Aug;23(15):3257-67
pubmed: 12102197
Expert Opin Drug Deliv. 2008 Sep;5(9):1039-46
pubmed: 18754752
Expert Rev Clin Pharmacol. 2016 Jun;9(6):747-9
pubmed: 26933755
Prog Retin Eye Res. 2014 Nov;43:17-75
pubmed: 25038518
Am J Ophthalmol. 1999 Mar;127(3):288-93
pubmed: 10088738
Biomater Sci. 2019 Nov 1;7(11):4603-4614
pubmed: 31436780
Biomaterials. 2011 May;32(14):3620-6
pubmed: 21320724
J Anat. 2011 Jul;219(1):44-52
pubmed: 21496013
Cell. 2012 May 11;149(4):847-59
pubmed: 22541070
Hum Mol Genet. 2005 Nov 1;14(21):3227-36
pubmed: 16174643
Br J Ophthalmol. 2015 May;99(5):618-23
pubmed: 25376617
Retina. 2011 May;31(5):915-23
pubmed: 21487341
Drug Deliv. 2018 Nov;25(1):1372-1383
pubmed: 29869520
Retina. 2014 Jan;34(1):18-23
pubmed: 24362413
Ophthalmology. 2019 Aug;126(8):1141-1154
pubmed: 30946888
Macromol Biosci. 2018 Feb;18(2):
pubmed: 29205853
J Ophthalmic Vis Res. 2009 Jul;4(3):191-3
pubmed: 23198073
Arch Pharm Res. 2004 Jan;27(1):1-12
pubmed: 14969330
Nat Commun. 2019 Jul 26;10(1):3347
pubmed: 31350409
Clin Ophthalmol. 2015 May 04;9:801-11
pubmed: 25999689
Biomed Pharmacother. 2018 Nov;107:1564-1582
pubmed: 30257375
Ageing Res Rev. 2015 Nov;24(Pt B):286-98
pubmed: 26369358
Biomacromolecules. 2012 Jan 9;13(1):40-8
pubmed: 22145634
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7331-7
pubmed: 26559479
Transl Vis Sci Technol. 2014 Dec 1;3(6):5
pubmed: 25653883
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
pubmed: 16452172
J Mater Sci Mater Med. 2013 Sep;24(9):2201-10
pubmed: 23677435
Transl Vis Sci Technol. 2018 Aug 28;7(4):21
pubmed: 30174998
Acta Ophthalmol. 2012 Jun;90(4):299-309
pubmed: 22112056
Adv Drug Deliv Rev. 2001 Oct 31;52(1):5-16
pubmed: 11672871
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Ophthalmology. 2010 Jun;117(6):1134-1146.e3
pubmed: 20417567
Br J Ophthalmol. 2004 Mar;88(3):365-70
pubmed: 14977771
Drug Discov Today. 2008 Feb;13(3-4):144-51
pubmed: 18275912
Sci Rep. 2017 Mar 10;7:44364
pubmed: 28281688
J Neuroinflammation. 2014 Jun 03;11:98
pubmed: 24889886
Eye (Lond). 2020 Aug;34(8):1371-1379
pubmed: 32071402
Int J Ophthalmol. 2015 Aug 18;8(4):653-8
pubmed: 26309857
Expert Opin Drug Deliv. 2014 Oct;11(10):1647-60
pubmed: 24975820
Transl Vis Sci Technol. 2014 Jul 1;3(4):8
pubmed: 25774328
Pharm Dev Technol. 2019 Jun;24(5):575-583
pubmed: 30457420
Prog Retin Eye Res. 2013 Nov;37:68-89
pubmed: 23933169
Int J Biol Macromol. 2013 Sep;60:272-6
pubmed: 23748006
Trans Am Ophthalmol Soc. 2008;106:206-13; discussion 213-4
pubmed: 19277236
Small. 2014 Apr 24;10(8):1575-84
pubmed: 24596245
Acta Ophthalmol. 2013 Aug;91(5):e340-7
pubmed: 23638803
Aten Primaria. 2006 Jun 15;38(1):51-7
pubmed: 16790220
Mol Vis. 2002 Apr 21;8:119-26
pubmed: 11979237
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1182-202
pubmed: 17107737
Exp Eye Res. 2008 Jan;86(1):41-51
pubmed: 17967453
Ulster Med J. 2005 Sep;74(2):82-92
pubmed: 16235759
J Control Release. 2015 Feb 28;200:71-7
pubmed: 25571784
Ophthalmology. 2012 Oct;119(10):2125-32
pubmed: 22727177
Mater Sci Eng C Mater Biol Appl. 2015 Dec 1;57:232-9
pubmed: 26354259
Biotechnol Bioeng. 2011 Jul;108(7):1716-25
pubmed: 21337339
Technol Health Care. 2019;27(S1):153-163
pubmed: 31045535
J Control Release. 2018 Sep 10;285:106-141
pubmed: 29964135
Ophthalmic Res. 2001 Jan-Feb;33(1):31-6
pubmed: 11114602
Pharm Res. 2018 Sep 25;35(11):217
pubmed: 30255364
Prog Retin Eye Res. 2009 Nov;28(6):423-51
pubmed: 19660572
Prog Mol Biol Transl Sci. 2015;134:449-63
pubmed: 26310170
Angew Chem Int Ed Engl. 2017 Jan 19;56(4):966-971
pubmed: 27918129
Nature. 2006 Oct 19;443(7113):787-95
pubmed: 17051205
AAPS PharmSciTech. 2019 Aug 9;20(7):281
pubmed: 31399890
Science. 1980 Dec 12;210(4475):1253-5
pubmed: 7434025
J Pharm Sci. 2009 Feb;98(2):529-42
pubmed: 18548615
Biomacromolecules. 2015 Oct 12;16(10):3093-102
pubmed: 26366887
J Ophthalmic Vis Res. 2011 Oct;6(4):317-29
pubmed: 22454753
Am J Ophthalmol. 2012 Apr;153(4):678-86, 686.e1-2
pubmed: 22245460
JAMA Ophthalmol. 2013 Dec;131(12):1595-601
pubmed: 24113783
Mol Pharm. 2013 Dec 2;10(12):4676-86
pubmed: 24131101
Br J Pharmacol. 2017 Jun;174(12):1719-1732
pubmed: 26754582
Bioeng Transl Med. 2019 Jun 10;4(2):e10128
pubmed: 31249878
J Ocul Pharmacol Ther. 2017 Mar;33(2):115-122
pubmed: 28055308
Expert Opin Drug Deliv. 2017 Feb;14(2):273-282
pubmed: 27434329
Arch Ophthalmol. 2002 Nov;120(11):1443-54
pubmed: 12427056
J Pharm Sci. 2015 Oct;104(10):3330-42
pubmed: 26108574
Expert Rev Ophthalmol. 2010 Feb 1;5(1):75-93
pubmed: 20305803
Arch Ophthalmol. 2002 Jun;120(6):797-803
pubmed: 12049586
Prog Neurobiol. 2010 Nov;92(3):293-315
pubmed: 20609379
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75
pubmed: 11006254
Am J Ophthalmol. 2007 Oct;144(4):618-26
pubmed: 17698021
Mol Pharm. 2019 May 6;16(5):1958-1970
pubmed: 30912953
Arch Ophthalmol. 2009 Dec;127(12):1581-3
pubmed: 20008710
Drug Deliv. 2016;23(3):710-26
pubmed: 24892625
Expert Opin Drug Deliv. 2012 Apr;9(4):383-402
pubmed: 22432690
J Ocul Pharmacol Ther. 2011 Jun;27(3):219-24
pubmed: 21574814
Int J Pharm. 2019 May 30;563:228-236
pubmed: 30959236
Adv Exp Med Biol. 2012;763:70-84
pubmed: 23397619
Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
pubmed: 11033038
Bioengineering (Basel). 2020 Jun 30;7(3):
pubmed: 32629806
Drug Deliv Transl Res. 2016 Dec;6(6):771-780
pubmed: 27178165
Neuron. 2012 Jul 12;75(1):26-39
pubmed: 22794258
Pharm Res. 1990 Nov;7(11):1190-4
pubmed: 2293220
Am J Ophthalmol. 2002 Sep;134(3):411-31
pubmed: 12208254
Expert Opin Pharmacother. 2013 Jun;14(8):1017-28
pubmed: 23560774
Nature. 1997 Apr 17;386(6626):671-4
pubmed: 9109485
Curr Eye Res. 2017 Sep;42(9):1293-1301
pubmed: 28557571
Eur J Pharm Biopharm. 2014 Nov;88(3):575-85
pubmed: 25092423
Drugs Aging. 2010 Feb 1;27(2):117-34
pubmed: 20104938
Retina. 2008 Apr;28(4):564-7
pubmed: 18398358
Mol Aspects Med. 2012 Aug;33(4):399-417
pubmed: 22510306
Expert Opin Drug Deliv. 2017 May;14(5):611-620
pubmed: 27551742
Br J Ophthalmol. 2006 Jan;90(1):75-80
pubmed: 16361672
Invest Ophthalmol Vis Sci. 2014 Jan 23;55(1):469-76
pubmed: 24370837
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Servir. 2009 Jan-Apr;57(1-2):46-56
pubmed: 21495402
Ophthalmologica. 2013;229(1):21-5
pubmed: 23006995
Medicina (Kaunas). 2016;52(2):79-88
pubmed: 27170480
Assay Drug Dev Technol. 2019 May/Jun;17(4):167-177
pubmed: 31184962
Expert Opin Drug Deliv. 2014 Jun;11(6):901-15
pubmed: 24848309
Transl Vis Sci Technol. 2015 Mar 10;4(2):5
pubmed: 25774331
Curr Eye Res. 2019 Mar;44(3):264-274
pubmed: 30295090
Prog Neurobiol. 2019 Feb;173:18-40
pubmed: 29864456
N Engl J Med. 2008 Jun 12;358(24):2606-17
pubmed: 18550876
Drugs Aging. 2002;19(2):101-33
pubmed: 11950377
Ann N Y Acad Sci. 2015 Nov;1358:1-12
pubmed: 26200808
Eur J Pharm Biopharm. 2015 Oct;96:217-25
pubmed: 26253504
J Physiol Paris. 2014 Feb;108(1):3-10
pubmed: 24270042
J Biomed Mater Res A. 2008 Dec 1;87(3):608-17
pubmed: 18186054
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3230-8
pubmed: 17591893
Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1217-1224
pubmed: 29134820
Eur J Pharm Sci. 2013 Nov 20;50(3-4):341-52
pubmed: 23933615
Eye (Lond). 2020 Aug;34(8):1341-1356
pubmed: 32001821
Macromol Biosci. 2015 Mar;15(3):405-13
pubmed: 25399803
Retina. 2009 May;29(5):699-703
pubmed: 19430280
Mol Vis. 1999 Nov 03;5:32
pubmed: 10562656
Int J Pharm. 2014 Aug 15;470(1-2):151-7
pubmed: 24768405
J Control Release. 2019 Mar 10;297:26-38
pubmed: 30664980
JAMA Ophthalmol. 2017 Jul 1;135(7):761-767
pubmed: 28570723
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):271-8
pubmed: 25592326
Eye (Lond). 2013 Jul;27(7):787-94
pubmed: 23722722
Arch Ophthalmol. 2008 Sep;126(9):1191-201
pubmed: 18779477
Neuron Glia Biol. 2011 Feb;7(1):25-40
pubmed: 22377033
J Biomed Mater Res B Appl Biomater. 2018 Aug;106(6):2472-2492
pubmed: 29247599
Eye (Lond). 2005 Sep;19(9):935-44
pubmed: 16151432
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Biochim Biophys Acta. 1989 Sep 18;984(3):384-7
pubmed: 2775784
Ophthalmology. 2011 Apr;118(4):626-635.e2
pubmed: 21459216
Open Ophthalmol J. 2012;6:54-8
pubmed: 22798970
Ther Deliv. 2017 Feb;8(2):89-107
pubmed: 28088880